IL-31 Antibody is affinity chromatography purified via peptide column.
Immunogen
IL-31 antibody was raised against a 18 amino acid synthetic peptide from near the center of human IL-31. The immunogen is located within amino acids 60 - 110 of IL-31.
IL31
Reaktivität: Human
ELISA
Wirt: Maus
Monoclonal
SB118b
Biotin
Applikationshinweise
IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 - 10 μ,g/mL. Despite its predicted size, IL-31 runs at approximately 27 - 30 kDa in SDS-PAGE. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
IL-31 Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
IL-31 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
IL-31 (IL31)
(Interleukin 31 (IL31))
Andere Bezeichnung
IL-31
Hintergrund
IL-31 Antibody: Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.